

Key Investor Information

This document provides you with key investor information about this Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Fund. You are advised to read it so you can make an informed decision about whether to invest.

Sygnia Health Innovation Global Equity Fund

a sub-Fund of PRESCIENT GLOBAL FUNDS ICAV (the "ICAV")

Share Class: B USD

This Fund is managed by Prescient Fund Services (Ireland) Limited (the "Manager")

Objectives and Investment Policy

The Fund's objective is to generate a net total return over a 5 year rolling period in excess of its Benchmark, the MSCI All Country World Index Net Total Return.

The objective is achieved mainly through investing in equity and equity-related securities of companies, which have exposure to the health innovation sector and supporting industries. The Fund will gain exposure to these companies primarily through direct investment in securities of such companies but may also invest indirectly in such securities (through investment up to 10% of its net assets via collective investment schemes).

The Fund may invest up to 100% of net assets in equities and equity-related securities, including, but not limited to, preferred stocks and warrants rights (which are issued by a company to allow holders to subscribe for additional securities issued by that company), as well as depository receipts (American Depository Receipts and Global Depository Receipts) for such securities.

The Fund may also hold cash or ancillary liquid assets (including money market instruments and cash deposits) pending investment or reinvestment. Such money market instruments include, but are not limited to, cash deposits, fixed or floating rate notes (i.e. short-term instruments issued under a legally binding facility (a form of revolving credit), which are underwritten by a bank or banks) and fixed or variable rate commercial paper (which are considered investment grade or above as rated by the principal rating agencies) and US treasury issues and shall be rated investment grade (BBB- or greater) (or equivalent) by Standard & Poor's, Moody's or Fitch. Up to 10% of the Net Asset Value of the Fund may be held in money market instruments at any time.

Investments will have a global focus provided that the Fund will not invest more than 30% of the Net Asset Value of the Fund in emerging markets.

The Fund may use financial derivative instruments (futures, options and forwards) for efficient portfolio management purposes (including hedging purposes), subject to the conditions and within the limits laid down by the Central Bank.

The Fund is considered to be actively managed in reference to the MSCI All Country World Index Net Total Return by virtue of the fact that it seeks to out-perform the Benchmark and it uses the Benchmark for the purpose of the calculation of the performance fee.


Any income arising from the Fund will be reinvested and it is not intended that the Fund will pay dividends.

The Fund is suitable for retail and professional investors with a high risk profile.

You may buy and sell shares in the Fund on each Business Day in Ireland.

Unless otherwise defined in this document, all words and expressions defined in the ICAV's current Prospectus shall have the same meaning herein. Please refer to the "Investment Objectives and Policies" section of the Prospectus and the "Investment Objective and Policy" section of the Supplement for further information.

Risk and Reward Profile of the Fund



The risk indicator is determined using historical data or, where historical data is not available, using simulated historical data. Historical data, such as is used in calculating the synthetic indicator, may not be a reliable indication of the future risk profile of the Fund. The risk category shown is not a target or a guarantee and may change over time. A category 1 fund is not risk free, the risk of loss is small but the chance of making gains may also be limited. With a category 7 fund, the risk of losing money is high but so also is the possibility of making gains. The risk indicator for the Fund is set at 6 as this reflects the market risk arising from proposed investments.

The Fund does not offer any capital guarantee or assurance that the investor will receive a fixed amount when redeeming.

In addition to the risk captured by the indicator, the overall Fund value may be considerably affected by:

- **Currency Risk** - the Fund may be exposed to currency risk in relation the valuation of assets held in currencies other than USD which fluctuate significantly over a short period of time.
- **Market Risk** - the Fund invests in shares of companies, and the value of these shares can be negatively affected

by changes in the company or its industry or the economy in which it operates.

- **Common Stocks Risk** – The value of a company's stock may fall as a result of factors relating directly to that company, such as decisions made by its management or lower demand for the company's products or services. A stock's value may also fall because of factors affecting not just the company, but companies in the same industry or in a number of different industries, such as increases in production costs. The value of a company's stock may also be affected by changes in financial markets that are relatively unrelated to the company or its industry, such as changes in interest rates or currency exchange rates.
- **Concentration Risk** - Risk implied from the possibility of failure of investments oriented to a certain common factor, such as business in the same branch or same geographical area or trading with the same commodity etc.
- **Settlement Risk** - reliability of trading and settlement systems may not be the same as more developed markets, resulting in delays in receiving proceeds when selling shares.
- **Liquidity Risk** - certain stock markets have low liquidity which means it may be more difficult to buy or sell shares than on a more developed market.

Please refer to the "Risk Factors" section of the Prospectus and the Supplement for further information - see under "Practical Information" for how to obtain a copy.

Charges for the Fund

These charges are used to pay the costs of running the Fund, including the costs of marketing and distribution. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest	
Entry charge	0%
Exit charge	0%
This is the maximum that might be taken out of your money before it is invested or before the proceeds of your investment are paid out.	
Charges taken from the Fund over a year	
Ongoing charges	1.34%
Charges taken from the Fund under certain specific conditions: Performance Fee:	

The Exit and Entry charges shown are maximum figures, and in some cases an investor may pay substantially less, or there will be no charges at all. You can find out the actual entry and exit charges from your financial advisor, distributor or the Manager.

The ongoing charges figure is an estimate based on a projection of the expenses of the Fund for the first twelve months of operation of the Fund, which includes estimates of any sales charges and ongoing charges which may be levied by the underlying collective undertakings into which the Fund invests.

This figure may vary from year to year. It excludes portfolio transaction costs, except in the case of an entry or exit charge paid by the Fund when buying or selling units in another UCITS or collective investment undertaking.

You can find more details about the charges in the section of the Prospectus entitled "Fees and Expenses" and in the Fund Supplement.

Past Performance

There is insufficient data for this Share Class to provide a useful indication of past performance.

Practical Information

Fund Depositary: Northern Trust Fiduciary Services (Ireland) Limited

Further Information: Copies of the Prospectus and the annual and half-yearly reports of the ICAV are available in English and may be obtained, free of charge, from the Manager at 35 Merrion Square East, Dublin 2, Ireland or by visiting www.prescient.ie.

Share Price / NAV: The net asset value of the Fund is calculated in USD. The unit prices are published in USD on each Business Day. The prices are available from the Investment Manager and the Manager during normal business hours and will be published on Prescient Fund Services (Ireland)'s website at www.prescient.ie.

Taxation: The Fund is subject to tax laws and regulations of Ireland. Depending on your home country of residence, this might have an impact on your investment. For further details, please speak to an adviser.

Switches: You are entitled to switch your shares to shares in the same class of another sub-Fund of the ICAV, subject to the sub-Fund's switching charge - see under "Charges for this Fund". Please refer to the Prospectus for further information on how to switch.

Fund Structure: This document describes a share class of Sygnia Health Innovation Global Equity Fund, a sub-Fund of the ICAV. The assets and liabilities of each sub-Fund of the ICAV are segregated subject to the provisions of Irish law. The Prospectus and Periodic Reports are prepared for the entire ICAV. You can find out more information about the ICAV in the Prospectus.

Remuneration: Details of the up-to-date remuneration policy of the Manager, including, but not limited to, a description of how remuneration and benefits are calculated, the identity of persons responsible for awarding the remuneration and benefits including the composition of the remuneration committee, if any, are available at www.prescient.ie. A paper copy of the remuneration policy will be made available free of charge upon request from the Manager.

Responsibility for Information: The Manager may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Prospectus for the Fund.

The ICAV is authorised in Ireland and approved by the Central Bank of Ireland. The Manager is authorised in Ireland and regulated by the Central Bank of Ireland. This Key Information Document is accurate as at 15 February 2022